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Abstract
Melatonin has been suggested as a new natural pain killer in inflammatory pain and during 
surgical procedures. We designed this randomized double-blind controlled study to evaluate 
the analgesic efficacy and also optimal preemptive dose of melatonin in patients undergoing 
cesarean section under spinal anesthesia . One hundred twenty patients scheduled for cesarean 
section under spinal anesthesia were randomly allocated to one of three groups of 40 each 
to receive melatonin 3 milligram (mg) (group M3), melatonin 6 mg (group M6) or placebo 
(group P) sublingually 20 min before the spinal anesthesia. The time to first analgesic request, 
analgesic requirement in the first 24 h after surgery, hemodynamic variables, anxiety scores nd 
the incidence of adverse events were recorded. The duration of anesthesia and analgesia didn’t 
show significant differences between three groups. Total analgesic request during 24 h after 
surgery was different among the three groups (P = 0.035). The incidence of headache in group 
M6 was significantly higher than others (P<0.001). However, after adjusting headache between 
groups of the study, we were unable to show the significant difference in the total analgesic 
request during 24 h after surgery among the three groups (p = 0.058). Although premedication 
of patients with 3 mg sublingual melatonin prolonged time to first analgesic request after 
cesarean delivery compared to placebo group, the difference was not statistically significant. 
Meanwhile increasing dose of melatonin to 6 mg failed to enhance analgesia and also increase 
the incidence of headache in patients undergoing cesarean section under spinal anesthesia.
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Introduction
Postoperative pain has a major impact on the 
recovery process and patient satisfaction after
Surgery (1). Good control of pain after 
cesarean section will improve mobility 
and can reduce the risk of thromboembolic 
events (2). Moreover, pain relief after 
cesarean delivery is associated with improved 
breastfeeding and infant rooming. Meanwhile, 
inadequate analgesia leads to elevated plasma 
catecholamine concentrations, which distress 
every organ system. The post-cesarean delivery 
pain is caused by surgical incision and uterus 
contraction with multiple mechanisms, which 
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includes both central and peripheral sensitization, 
and also descending inhibition pathway (3). 
Therefore, non-steroidal anti-inflammatory 
agents (NSAIDs) and opioids play important 
roles in the management of pain. However, in 
parturient period, beneficial analgesia has to 
be balanced against known fetal and maternal 
effects, including respiratory depression, arterial 
hypotension, emetogenesis, pruritus, and direct 
and indirect irritation of the gastrointestinal tract 
(3).  Such adverse effects may hamper the early 
post-operative recovery and quick breastfeeding 
and infant rooming. Therefore, the potential 
clinical advantages of new drugs in this setting 
remain to be evaluated. Melatonin or N-acetyl-
methoxy tryptamine is mainly a neurohormone 
produced by the pineal gland. Melatonin has been 
suggested as a new analgesic drug and natural 
pain killer in inflammatory and neuropathic 
pain as well as surgical procedures (4, 5). It is 
reported that melatonin inhibits inflammation 
and tissue injury by affecting COX-2 and nitric 
oxide activity (4, 5, 6). The favorable role of 
melatonin in placental and fetal well-being is 
frequently reported (7, 8). Melatonin specifically 
distracts the circadian rhythms and promotes 
fetal growth and neurogenesis. Also, there is 
no evidence of unfavorable fetal or neonatal 
outcomes after its use (7, 8). In addition, the 
similarities between melatonin and oxytocin 
signaling might be leading to reduce blood loss 
via increased contractility of myometrium (9). 
Hence, these favorable effects may be valuable 
when melatonin is used as a premedication for 
cesarean section under spinal anesthesia. Use of 
melatonin as an anxiolytic agent has been studied 
extensively in human and animals (10-17). 
Although, there is evidence that in non-obstetric 
patients, melatonin decreases postsurgical 
pain, but the results of the previous studies are 
conflicting in gynecology/obstetrics. Also, an 
optimal melatonin dose with analgesic potentials 
is still unclear (11-18). According to the best of 
our knowledge, this study is the first in which 
the analgesic effect of melatonin in cesarean 
section has been evaluated. Our hypothesis was 
that melatonin may decrease the severity of pain 
after cesarean section without produce serious 
side effects apart from the anxiolytic effects 
during cesarean section under spinal anesthesia.
Methods
Following Ethics Committee approval 
and taking informed consents, we recruited 
135 patients in a prospective, double-blind, 
randomized parallel trial in the Kowsar 
Hospital, Qazvin, Iran from April 2012 to 
October 2012. The patients were in a range of 
18-40 year-old with an ASA physical status I 
or II who were scheduled for cesarean section 
under spinal anesthesia. The Consolidated 
Standards of Reporting Trials (CONSORT) 
recommendations for reporting randomized, 
controlled clinical trials were followed (Figure 
1.) (19). Exclusion criteria included significant 
coexisting  disease such as hepatorenal diseases, 
psychotic disorders, chronic cardiovascular 
disease, history of chronic headache, any 
contraindication to regional anesthesia such as 
local infection or bleeding disorders, allergy to 
melatonin, long-term antidepressant or analgesic 
drug use, any risk factor associated with an 
increased risk of postpartum hemorrhage such 
as  multiple gestation, antepartum hemorrhage, 
polyhydramnios, and a history of previous 
rupture uterus. Patients were randomly allocated 
to one of three groups of 40 each to receive 
melatonin 3 milligram (mg) (Melatonin, Natural 
Webber; Canada) (group M3), melatonin 6 mg 
(Melatonin, Natural Webber; Canada) (group 
M6) or placebo (group P) sublingually 20 min 
before the spinal anesthesia. Randomization was 
undertaken by means of computer generated 
random number in sealed opaque envelops. 
Allocation was managed by a resident external 
to the project and the study drugs given by a 
nurse non–involved in the study. The anesthetist 
was blinded to the patient’s group assignment, 
and the study data were recorded by a blinded 
observer. No premedication was given except for 
the drugs predetermined by the study protocol. 
All patients received an intravenous preload of 
5-7 mL/Kg lactated Ringer’s solution before 
a subarachnoid block. After using an aseptic 
technique, a 25-gauge Quincke needle was 
inserted intrathecally via a midline approach into 
the L4-5 interspaces with the patient in the sitting 
position by the same resident. Immediately after 
delivery of the neonate, intravenous infusion 
of oxytocin (20 IU syntocinon dissolved in 0.5 
liter of lactated Ringer’s solution) over a 15 min 
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period, was administered. Additional oxytocin 
(2.5 IU) was bolus injected if the surgeon 
considered uterine tone to be inadequate.  At the 
preoperative visit, the verbal anxiety score (VAS) 
ranging from 0 to 10 (0= completely calm, 10= 
the worst possible anxiety) were explained to 
patients. The verbal anxiety score (VAS) ranging 
of patients was assessed at before premedication, 
before spinal anesthesia, 5 min after spinal 
anesthesia, after delivery of neonate, 15 min 
after spinal anesthesia, and after the surgery at 
recovery room. The primary outcomes of this 
randomized, double blinded placebo-controlled 
clinical trial were to evaluate the time to first 
requirement of analgesic supplement and total 
analgesic consumption in the first postoperative 
24 h. The duration of spinal anesthesia was 
defined as the time from spinal injection to 
the first occasion when the patient complained 
of pain in the post-operative period. Also, the 
postoperative analgesia was defined as the time 
to the first requirement of analgesic supplement 
from the time of injection. No additional 
analgesic was administered unless requested 
by the patient. Patients were preoperatively 
instructed to use the verbal pain scale (VPS) 
from 0 to 10 (0: no pain, 10: maximum 
imaginable pain) for pain assessment.  If the 
VPS exceeded four and the patient requested a 
supplement analgesic, a suppository (100 mg) 
of sodium diclofenac was given to relieve the 
post-operative pain as needed. For breakthrough 
pain (VPS >4) if the time for administration 
of diclofenac Na decreased to less than 8h, 
pethidine 25 mg was given intravenously (IV). 
The secondary outcomes of this study included 
the assessment of hemodynamic variables, 
anxiety scores, the incidence of hypotension, 
ephedrine requirements, bradycardia, hypoxemia 
[saturation of peripheral oxygen (SpO2) <90], 
adverse events such as nausea and vomiting, 
headache and APGAR score of neonates. 
Based on the data from previous similar 
studies, a sample size of 28 patients per group 
was required to detect a 20-min difference in 
the mean duration of analgesia between the 
groups with β = 0.1, and α = 0.05(11-14). We 
included 40 patients in each group to allow 
for probable dropouts and protocol violations. 
Data were analyzed using SPSS (SPSS 15.0, 
SPSS Inc, Chicago, IL, USA). Continuous 
variables were tested for normal distribution 
by the Kolmogorov–Smirnov test. Normally 
distributed data were expressed as means and 
standard deviations (SD). Analysis of variance 
(ANOVA)and repeated measures analyses were 
Figure 1. Consort flow diagram.
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used for continuous parametric variables. Within 
groups comparisons were made using the LSD 
Post-hoc analysis. Chi square and Fisher›s exact 
tests were used for comparison the incidence of 
side effects between the groups. A pvalue<0.05 
was considered as significant, statistically.
Results
Of total one hundred thirty five patients 
initially enrolled in this study, 15 patients had to 
be excluded because of logistical reasons or other 
violations of the study protocol. One hundred 
twenty patients were included and randomly 
assigned to their treatment groups (Figure 1). 
No significant differences in age, stature, and 
weight among the three groups were found. The 
duration of surgery was also similar (Table 1.).
Table 2. shows that mean time of duration of 
anesthesia was longer in group M3 (83.47 ± 24. 
77) than in groups M6 (79.72  ± 25.83) and P 
(70.68  ± 24.77min), but the difference between 
three groups were insignificant. Meanwhile, as 
shown in Table 2. the mean time to first analgesic 
request was also longer in group M3 (208.19 ± 
122.66) than in groups M6 (196 ± 127.25) and P 
(152.13 ± 79.4 min), but the difference between 
three groups were not significant.
The difference of total number of analgesic 
request by patients during 24 h after surgery 
among three groups were significant (P = 0.035). 
The total of analgesic request by patients during 
24 h after surgery was significantly lower in 
M3 group compared to P group (P = 0.024) and 
M6 group (P = 0.024) while there wasn’t any 
difference between M6 and placebo groups (P = 
0.975) through LSD post hoc test. Figure 2. shows 
that the frequency of patients who requested 
analgesic at least four times was greater in 
placebo compared to M3 group. On contrary, the 
frequency of patients who requested analgesic 
only once was greater in groupM3 compared to 
other two groups.
As shown in Table 3. apart of headache, no 
significant differences were found in the three 
groups in terms of other intraoperative and 
postoperative side effects including pruritus, 
nausea, vomiting, vertigo and respiratory 
depression. The incidence of headache in group 
M6 was significantly higher than other groups 
(P<0.001).
After adjusting headache between groups of 
the study, we were unable to show the observed 
difference in the total number of analgesic 
request by patients during 24 h after surgery any 
more among the three groups (p = 0.058).
Table 1.  Demographic data associated with the study groups.
Groups P (N=38) M6 (N=40) M3 (N=36) PValue
Weight (kg) 75.21±7.15 72.45±6.59 74.75±6.88 0.169
Height (cm) 161.6±3.78 160.98±3.17 160.56±3.18 0.409
Age (years) 28.63±5.31 28.38±5.67 28.19±6.21 0.947
Duration of surgery 
(min) 85.63 ± 15.70 79.16±20.11 81.70±18.76 0.840
Values are presented as mean±SD.
Table 2. Comparison of  analgesic duration  in three study groups.
PvalueM3 (N=36)M6 (N=40)P (N=38)Groups
0.09083.47±26.26*79.77±25.8370.68±24.77
ِDuration of spinal 
anesthesia (min)
0.076208.19±122.66*196.82±127.25152.13±79.4
Time to first analgesic 
request
Values are presented as mean±SD.*As mentioned in the text, P values from LSD test of Post  Hoc analysis  in M3  versus P groups were 
significant.
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As shown in Figure 3. comparison of anxiety 
scores between three groups revealed significant 
difference through repeated measures analysis 
(P = 0.024). The anxiety score decreased 
significantly in the group of 6 mg melatonin 
compared to the placebo group through a 
repeated measures analysis and Scheffe’s post 
hoc test (p = 0.043).
Transient hypotension occurred at various 
time points in three groups, despite pre-block 
volume loading. These patients were treated 
with 5mg of ephedrine (boluses IV) to maintain 
systolic blood pressure (SBP) within 20% of 
baseline values or 90 mmHg. Comparison of 
mean arterial pressure (MAP) (P = 0.547) and 
heart rate (HR) (P = 0.227) changes during 
spinal anesthesia and surgery failed to reveal 
any statistically significant differences between 
all groups through repeated measure analysis. 
The mean variations of MAP and HR were 
defined as the difference between the highest 
and the lowest mean arterial pressure and heart 
rate in each patient and compared between 
the groups. Table 4. shows that difference of 
MAP variation between three groups were 
insignificant (P = 0.063) as well as the overall 
difference in ephedrine requirement (P = 0.239). 
Also, as shown in Table 4. the difference of 
mean HR variation between three groups were 
insignificant (P = 0.712).
All newborns in our study were free of any 
adverse effect. The Apgar scores at first (P = 
0.212) and five (P = 0.367) minutes after delivery 
in the three groups were statistically similar. 
Discussion
Based on the data found in our study, 
we concluded that although premedication 
of patients with 3 mg sublingual melatonin 
prolongs time to first analgesic request after 
cesarean delivery compared to placebo group but 
the difference was not statistically significant. 
Meanwhile increasing dose of melatonin to 6 
mg failed to enhance analgesia and also increase 
the incidence of headache in patients undergoing 
cesarean section under spinal anesthesia. Our 
results with regard to the analgesic effect of 
melatonin are consistent with some previous 
studies (15-18). The findings of our previous 
studies and two studies carried out by Naguib 
et al. also indicating that there is no significant 
difference in the intraoperative opioid use or 
total doses of analgesics consumption in the 
melatonin or placebo groups over ninety min 
after the end of anesthesia at post-anesthesia care 
unit (15, 17). Yousaf et al. also in a systematic 
analysis of qualified clinical trials suggested 
Figure 2. Comparison of total number of analgesic request in the first 24 h postoperative in the three groups.
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that the analgesic effects of melatonin during 
the perioperative period is limited and results 
remain controversial (18). However, several 
previous studies reported that pain scores in the 
melatonin group, were significantly lower than 
in the control group. Anywise, these apparently 
controversial findings may be due to either the 
difference in melatonin doses or dissimilarity in 
population and the kind of surgeries, anesthesia 
(11, 14) .However the analgesic properties of 
melatonin have been shown to depend on the 
inhibition of inflammatory pathway and tissue 
injury by affecting COX-2 and nitric oxide 
activity (20,  21). Furthermore there is evidence 
that melatonin modulates glutamatergic systems 
involve the NMDA receptor  Some results of 
present study are also supported by recent studies 
which  suggested that melatonin can display 
its antinociceptive effects through indirect 
interacting  with  a number of neurotransmitter 
systems including benzodiazepinergic receptor, 
opioidergic and sigma receptor, serotonergic, 
dopaminergic, adrenergic, glutamatergic 
(NMDA receptor), NO-cyclic GMP-PKG 
signaling pathway, and directly through 
melatoninergic MT
1
/MT2 receptors (21-23). 
We chose to administer melatonin sublingually 
20 min before the surgery in our study because 
the onset of melatonin-induced sedation has 
been reported to appear approximately 20-30 
min after administration and the melatonin 
concentration remains stable for approximately 
1.5 h at its peak concentration (24). Since the 
optimal effective analgesic dose of melatonin 
is still unclear, we chose to administer 3 and 
6 mg of melatonin because these are the most 
Figure 3. Comparison of Anxiety Scores in three study groups.
Table 3. Side effects observed in three study groups.
PvalueM3 (N=36)M6 (N=40)P (N=38)Groups
0.15202(%5)0Pruritus
1.000000Respiratory depression
0.35113 (%36.1)17 (%242.5)20 (%52.6)Nausea
0.1555 (%13.9)12 (%30)12 (%31.6)Vomiting
<0.0012(5.6%)18 (%45)4(10.5%)Headache
0.05803 ((%7.5)0Vertigo
Data are presented as number of patients (%). P=placebo, M3= Melatonin 3mg, M6= melatonin 6 mg.
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commonly used dose of melatonin in both acute 
and chronic pain studies  The next observation of 
study which should be noted is that the total of 
analgesic request by patients during 24 h after 
surgery was significantly lower in M3 group 
compared to other groups while there wasn’t 
any difference between M6 and placebo groups 
(18). Despite to the previous study in rats by 
Yu, Zhu et al., which reported that  melatonin 
produces dose-dependent antinociceptive 
effects (21, 25). we could not demonstrate the 
dose-dependent antinociceptive effects for 
melatonin. However, in other previous studies, a 
similar hypnotic effect for melatonin at the dose 
between 0.3 and 10 mg was reported, a finding 
partially in accordance with that obtained in our 
study (26, 27). In present study increasing dose 
of melatonin to 6 mgnot only failed to enhance 
analgesia but also increased the incidence of 
headache in patients undergoing cesarean section 
under spinal anesthesia compared to M3 and 
control group. However, this finding indicates 
that sublingual melatonin could produce minor 
analgesic effects. The other possible explanation 
for this finding could be simultaneous application 
of spinal anesthesia   and high dose melatonin 
may be associated with an increase in headache 
prevalence and thereby it induced shortening 
the time to first analgesic request in this group. 
In this study, after adjusting headache between 
groups of the study, we were unable to show 
the observed significant difference. Anywise we 
cannot offer a satisfactory good explanation for 
this finding and future studies are needed. 
In present study, despite the fact that a 
beneficial effect in treating migraine and cluster 
headache for melatonin in the several studies 
(28, 30). were reported, we observed the higher 
incidence of headache in patients who received 
6mg melatonin. Peres et al. declared that a number 
of mechanisms like free radical scavenging, 
anti-inflammatory effects, inhibition of nitric 
oxide activity and dopamine release, GABA 
potentiation and neurovascular regulation, have 
been responsible for the favorable effects of 
melatonin in the treatment of cluster headaches 
and migraine attacks (28-30). However, there is 
general agreement that postpartum headache is 
a common troublesome complaint that can be 
worsened or caused by several factors ranging 
from hormonal shifts, physiological changes 
and peripartum procedures (31). In present 
study we excluded patients who had history 
of primary chronic headache. Since there is 
general agreement that the occurrence of PDPH 
(postdural puncture headache) following spinal 
anesthesia is influenced to some degree by 
anesthetic technique, with atraumatic (pencil-
point) and smaller sized needles, these factors 
were controlled among the treatment groups 
in our study (32-34). In present study spinal 
anesthesia was performed by the same resident 
of anesthesiology in one technique which was 
described in the method section. The authors of 
the present study speculate that the high dose 
of melatonin may be augment the headache 
due to low cerebrospinal fluid (CSF) pressure 
and intracranial hypotension induced by the 
dural puncture. Dehghan et al. declared that 
daily administration of melatonin for 72 h after 
TBI (Traumatic Brain Injury) is effective in 
decreasing ICP and brain edema and improving 
neurological scores (34). According to another 
studies, melatonin therapy causes brain edema 
reduction and oral administration of melatonin 
1 h prior and 1 h after ischemia induction in rats 
decreases brain edema (36, 37). Nevertheless, 
we cannot offer adequate explanation for 
this finding and further studies in large and 
different population are needed. Future studies 
Table 4. Changes in hemodynamic variables.
PvalueM3 (N=36)M6 (N=40)P (N=36)Groups
0.06343.66±11.0546.37±14.5444.5±14.27variation of MAP
0.71242.03±16.9241.02±16.3636.73±12.82variation of HR
Values are presented as mean ± SD, MAP = mean arterial blood pressure (mmHg); HR = heart rate (bpm). P = placebo, M3=Melatonin 3 
mg, M6 = melatonin 6 mg. The mean variation of MAP and HR was defined as the difference between the highest and the lowest mean 
arterial pressure and heart rate in each patient.
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are necessary to evaluate the analgesic efficacy 
of melatonin in patients undergoing cesarean 
section under general anesthesia.
Conclusion
Based on the study, we concluded that 
premedication of patients with 3 mg sublingual 
melatonin provided minor analgesic effects 
compared to placebo group. Meanwhile 
increasing dose of melatonin to 6 mg failed 
to enhance analgesia and also increase the 
incidence of headache in patients undergoing 
cesarean section under spinal anesthesia.
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